drugset
drugset / Trial / NCT02991508

Adrecizumab Phase 1 Trial

NCT02991508 ↗

Phase 1 Completed 24 enrolled Radboud University Medical Center Adrenomed AG · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This is the first clinical trial with ADRECIZUMAB. The purpose of this clinical trial to identify safety and tolerability of different doses of ADRECIZUMAB in healthy volunteers.

Timeline

Start
2016-05-23
Primary completion
2016-09-22
Completion
2016-09-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator ENIBARCIMAB Monoclonal antibody 0.5 mg/kg Intravenous
Comparator ENIBARCIMAB Monoclonal antibody 2 mg/kg Intravenous
Comparator ENIBARCIMAB Monoclonal antibody 8 mg/kg Intravenous

Indications

No indication recorded.